These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15675578)

  • 1. [Second-line chemotherapy for recurrent ovarian cancer].
    Sugiyama T
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):28-32. PubMed ID: 15675578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ovarian cancer].
    Sugiyama T
    Gan To Kagaku Ryoho; 2005 Aug; 32(8):1096-103. PubMed ID: 16121909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of platinum-resistant ovarian cancer].
    Onishi Y; Nakamura T; Hatae M
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
    [No Abstract]   [Full Text] [Related]  

  • 5. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
    Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
    Ueda Y; Enomoto T; Matsuzaki S; Kobayashi E; Kimura T; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1411-6. PubMed ID: 23515753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
    Isonishi S; Niimi S; Sasaki H; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Jun; 93(3):647-52. PubMed ID: 15196859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
    Ota T; Takeshima N; Takizawa K
    Eur J Gynaecol Oncol; 2011; 32(5):471-5. PubMed ID: 22053655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advances in ovarian cancer chemotherapy].
    Hatae M; Onishi Y; Kume H; Maeda Y; Nakagawa S; Hokanishi H
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1982-90. PubMed ID: 1384436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
    McGuire WP
    J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.